← All trials
NCT04728334
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 27, 2021
- Primary completion
- Jan 27, 2022
- Completion date
- Jan 27, 2023
- First posted
- Jan 28, 2021
- Last posted
- Jan 28, 2021
- Enrollment
- 162
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Akeso Pharmaceuticals, Inc.Lead sponsor
- Fudan UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.